Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

25C-NBOH: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Kenan
m Use psychedelics template
>Graham
m some wiki ref formatting (science papers + links that worked)
 
(10 intermediate revisions by 4 users not shown)
Line 1: Line 1:
[[SubstanceClassAlias::25x-NBOH| ]]
 
{{Headerpanel|{{Warning/25C-NBOH}}}}
{{Headerpanel|{{Warning/25C-NBOH}}}}
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/25C-NBOH}}
{{SubstanceBox/25C-NBOH}}


'''25C-NBOH''' (also known as '''2C-C-NBOH''' and '''NBOH-2CC''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class that produces an array of visually-dominant and [[stimulating]] [[psychedelic]] effects when [[Routes of administration|administered]]. It is a closely related analog of [[25B-NBOMe]] and is reported to share most of its properties with the exception of a moderately reduced potency and a shorter duration.
'''25C-NBOH''' (also known as '''2C-C-NBOH''' and '''NBOH-2C-C''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class that produces an array of visually-dominant and [[stimulating]] [[psychedelic]] effects when [[Routes of administration|administered]]. It is a closely related analog of [[25B-NBOMe]] and is reported to share most of its properties with the exception of a moderately reduced potency and a shorter duration.


The name 25C-NBOH, which is short-hand for 2C-C-NBOH, is a derivative of the phenethylamine psychedelic [[2C-C]]. It was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen.<ref>Martin Hansen (2011). "Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain." University of Copenhagen. Retrieved 27 June 2015.</ref>
The name 25C-NBOH, which is short-hand for 2C-C-NBOH, is a derivative of the phenethylamine psychedelic [[2C-C]]. It was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen.<ref>{{cite book | vauthors=((Hansen, M.)) | date= 2010 | title=Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain: PhD thesis | publisher=Faculty of Pharmaceutical Sciences, University of Copenhagen | isbn=9788792719003}}</ref>


It is worth noting that compounds of the NBOH family are not [[orally]] active and should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes.
It is worth noting that compounds of the NBOH family are not [[orally]] active and should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes.


Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOH in humans. It has no history of human use before being sold online as a [[designer drug]] in 2011.{{citation needed}} It is closely related to members of the [[25x-NBOMe]] series, which have been associated with many hospitalizations and deaths.<ref name="25Ifatal">25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml</ref><ref name="25Cfatal">25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml</ref><ref name="25Xfatal">Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml</ref> Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects.
Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOH in humans. It has no history of human use before being sold online as a [[designer drug]] in 2011.{{citation needed}} It is closely related to members of the [[25x-NBOMe]] series, which have been associated with many hospitalizations and deaths.<ref name="25Ifatal">{{Citation | title=Erowid 25I-NBOMe (2C-I-NBOMe) Vault : Fatalities / Deaths | url=https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml}}</ref><ref name="25Cfatal">{{Citation | title=Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths | url=https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml}}</ref><ref name="25Xfatal">{{Citation | title=Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault : Fatalities / Deaths | url=https://www.erowid.org/chemicals/nbome/nbome_death.shtml}}</ref> Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects.


==Chemistry==
==Chemistry==
Line 19: Line 19:
25C-NBOH has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a potent [[Agonist#Agonists|agonist]].  
25C-NBOH has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a potent [[Agonist#Agonists|agonist]].  


This compound is pharmacologically unique when compared to other psychedelics due to the unusually high selectivity it displays for various [[serotonin]] receptors. It is notable as one of the most selective agonist ligands for the 5-HT<sub>2A</sub> receptor with a pEC<sub>50</sub> value of 9.43<ref>Silva, M. E., Heim, R., Strasser, A., Elz, S., & Dove, S. (2011). Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor. Journal of Computer-aided Molecular Design, 25(1), 51-66. https://doi.org/10.1007/s10822-010-9400-2</ref>
This compound is pharmacologically unique when compared to other psychedelics due to the unusually high selectivity it displays for various [[serotonin]] receptors. It is notable as one of the most selective agonist ligands for the 5-HT<sub>2A</sub> receptor with a pEC<sub>50</sub> value of 9.43<ref>{{cite journal | vauthors=((Silva, M. E.)), ((Heim, R.)), ((Strasser, A.)), ((Elz, S.)), ((Dove, S.)) | journal=Journal of Computer-Aided Molecular Design | title=Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor | volume=25 | issue=1 | pages=51–66 | date= January 2011 | url=http://link.springer.com/10.1007/s10822-010-9400-2 | issn=0920-654X | doi=10.1007/s10822-010-9400-2}}</ref>


It acts as a potent [[serotonin]] [[receptor]] [[agonist]] with similar affinity to the better-known compound [[25C-NBOMe]] at 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors with pKis values of 9.4 and 7.8, respectively.<ref>Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Bräuner-Osborne, H., & Kristensen, J. L. (2014). Synthesis and structure–activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists. ACS Chemical Neuroscience, 5(3), 243-249. https://doi.org/10.1021/cn400216u</ref>
It acts as a potent [[serotonin]] [[receptor]] [[agonist]] with similar affinity to the better-known compound [[25C-NBOMe]] at 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors with pKis values of 9.4 and 7.8, respectively.<ref>{{cite journal | vauthors=((Hansen, M.)), ((Phonekeo, K.)), ((Paine, J. S.)), ((Leth-Petersen, S.)), ((Begtrup, M.)), ((Bräuner-Osborne, H.)), ((Kristensen, J. L.)) | journal=ACS Chemical Neuroscience | title=Synthesis and Structure–Activity Relationships of N -Benzyl Phenethylamines as 5-HT 2A/2C Agonists | volume=5 | issue=3 | pages=243–249 | date=19 March 2014 | url=https://pubs.acs.org/doi/10.1021/cn400216u | issn=1948-7193 | doi=10.1021/cn400216u}}</ref>


However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
Line 151: Line 151:
{{#ask: [[Category:25C-NBOH]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:25C-NBOH]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_25INBOMe.shtml Erowid Experience Vaults: 25C-NBOH]
 
*[https://www.erowid.org/experiences/subs/exp_25CNBOH.shtml Erowid Experience Vaults: 25C-NBOH]


==Toxicity and harm potential==
==Toxicity and harm potential==
Line 158: Line 159:
25C-NBOH is a relatively new substance, and little is known about its toxicity or interaction with other substances. It is assumed to pose similar acute health risks as 25C-NBOMe and other members of 25x-NBOMe series. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it is likely to be [[Toxicity::potentially fatal at heavy dosages]].  
25C-NBOH is a relatively new substance, and little is known about its toxicity or interaction with other substances. It is assumed to pose similar acute health risks as 25C-NBOMe and other members of 25x-NBOMe series. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it is likely to be [[Toxicity::potentially fatal at heavy dosages]].  


25C-NBOH's extreme potency means it should not be [[insufflated]] (snorted) as this method of administration has been associated with many deaths and hospitalizations with closely related members of the [[25x-NBOMe]] series.<ref name="25Ifatal">25I-NBOMe (2C-I-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml</ref><ref name="25Cfatal">25C-NBOMe (2C-C-NBOMe) Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_death.shtml</ref><ref name="25Xfatal">Other or Unknown NBOMe Compound Fatalities / Deaths by Erowid | https://www.erowid.org/chemicals/nbome/nbome_death.shtml</ref>
25C-NBOH's extreme potency means it should not be [[insufflated]] (snorted) as this method of administration has been associated with many deaths and hospitalizations with closely related members of the [[25x-NBOMe]] series.<ref name="25Ifatal"/><ref name="25Cfatal"/><ref name="25Xfatal"/>


===Tolerance and addiction potential===
===Tolerance and addiction potential===
Line 169: Line 170:
{{DangerousInteractions/Psychedelics}}
{{DangerousInteractions/Psychedelics}}


==Legality==
==Legal status==
{{legalStub}}
{{legalStub}}
*'''United Kingdom''' - 25C-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made</ref>
 
*'''Sweden:''' The Riksdag added 25C-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12<ref> https://lakemedelsverket.se/upload/lvfs/HSLF_FS_2015_12.pdf</ref>
*'''Brazil''': As of December 10, 2018, 25C-NBOH has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.<ref>List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial</ref>
*'''Germany''': 25C-NBOH is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl116s2615.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl116s2615.pdf%27%5D__1576017393518|title=Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe|publisher=Bundesanzeiger Verlag|access-date=December 11, 2019|language=de}}</ref><ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/anlage.html|title=Anlage NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref> Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.<ref>{{cite web|url=https://www.gesetze-im-internet.de/npsg/__4.html|title=§ 4 NpSG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref>
*'''Sweden''': The Riksdag added 25C-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12<ref>https://lakemedelsverket.se/upload/lvfs/HSLF_FS_2015_12.pdf</ref>
*'''Switzerland''': 25C-NBOH is a controlled substance specifically named under Verzeichnis E.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': 25C-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>{{Citation | year=2014 | title=Misuse of Drugs Act 1971 (S.I. 2014/1106) | publisher=London: The Stationery Office Limited | url=https://www.legislation.gov.uk/uksi/2014/1106/made | access-date=5 July 2017}}</ref>


==See also==
==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Research chemical]]
*[[Research chemical]]
Line 183: Line 189:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/25C-NBOH 25C-NBOH (Wikipedia)]
*[https://en.wikipedia.org/wiki/25C-NBOH 25C-NBOH (Wikipedia)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=1252 25C-NBOH (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=1252 25C-NBOH (Isomer Design)]
Line 188: Line 195:
==References==
==References==
<references />
<references />
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Psychedelic]]
[[Category:25x-NBOH]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Phenethylamine]]
 
[[Category:Psychedelic]]
{{#set:Featured=true
{{#set:Featured=true
}}
}}

Latest revision as of 07:18, 30 June 2022

25C-NBOH may result in severe injury or death.

While no deaths have been reported, it is likely that this compound shares a similar toxicity profile with 25C-NBOMe (which has been linked to multiple deaths).[1] It is strongly discouraged to take higher doses of this substance or to insufflate (snort) it. Please see this section for more details.

Summary sheet: 25C-NBOH
25C-NBOH
Chemical Nomenclature
Common names 25C-NBOH
Substitutive name 2C-C-NBOH
Systematic name [[systematic name::2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-hydroxyphenyl)methyl]ethanamine]]
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





Sublingual
Dosage
Threshold 100 µg
Light 250 - 500 µg
Common 500 - 750 µg
Strong 750 - 1000 µg
Heavy 25C-NBOH may be fatal at heavy doses.
Duration
Total 5 - 7 hours
Onset 15 - 45 minutes
Come up 30 - 90 minutes
After effects 3 - 6 days







DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions


25C-NBOH (also known as 2C-C-NBOH and NBOH-2C-C) is novel synthetic psychedelic substance of the phenethylamine chemical class that produces an array of visually-dominant and stimulating psychedelic effects when administered. It is a closely related analog of 25B-NBOMe and is reported to share most of its properties with the exception of a moderately reduced potency and a shorter duration.

The name 25C-NBOH, which is short-hand for 2C-C-NBOH, is a derivative of the phenethylamine psychedelic 2C-C. It was first synthesized and documented in 2011 by Martin Hansen at the University of Copenhagen.[2]

It is worth noting that compounds of the NBOH family are not orally active and should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes.

Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25C-NBOH in humans. It has no history of human use before being sold online as a designer drug in 2011.[citation needed] It is closely related to members of the 25x-NBOMe series, which have been associated with many hospitalizations and deaths.[3][1][4] Anecdotal reports suggest that this substance may be difficult to use safely due to its highly sensitive dose-response and unpredictable effects.

Chemistry

25C-NBOH or 2C-C-NBOH, is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-C. 25C-NBOH is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as an bromine atom attached to carbon R4. It differs from 2C-C structurally through a substitution on the amine (NH2) with a 2-hydroxybenzyl (BOH) group. 25C-NBOH shares this 2-hydroxybenzyl substitution with other chemicals of the NBOH family. This NBOH addition is comprised of a hydroxy ether OH- bound to a benzene ring at R2.

Pharmacology

Further information: Serotonergic psychedelic

25C-NBOH has efficacy at the 5-HT2A receptor where it acts as a potent agonist.

This compound is pharmacologically unique when compared to other psychedelics due to the unusually high selectivity it displays for various serotonin receptors. It is notable as one of the most selective agonist ligands for the 5-HT2A receptor with a pEC50 value of 9.43[5]

It acts as a potent serotonin receptor agonist with similar affinity to the better-known compound 25C-NBOMe at 5-HT2A and 5-HT2C receptors with pKis values of 9.4 and 7.8, respectively.[6]

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

25C-NBOH is a relatively new substance, and little is known about its toxicity or interaction with other substances. It is assumed to pose similar acute health risks as 25C-NBOMe and other members of 25x-NBOMe series. The LD50 has not yet been determined although it is likely to be potentially fatal at heavy dosages.

25C-NBOH's extreme potency means it should not be insufflated (snorted) as this method of administration has been associated with many deaths and hospitalizations with closely related members of the 25x-NBOMe series.[3][1][4]

Tolerance and addiction potential

25C-NBOH is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25C-NBOH is built almost immediately after ingestion. After that, it takes about 1 week for the tolerance to be reduced to half and 2 weeks to be back at baseline (in the absence of further consumption). 25C-NBOH presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 25C-NBOH all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • [[Wikipedia:Lithium_(medication)|DangerousInteraction::Lithium]] - Lithium is commonly prescribed for the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Cannabis may have an unexpectedly strong and unpredictable synergy with the effects of 25C-NBOH. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid unintentional overdose.
  • "[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Stimulants like amphetamine, cocaine or methylphenidate affect many parts of the brain and alter dopaminergic function. This combination can increase the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also result in an elevated risk of mania and psychosis.[citation needed]
  • "[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Tramadol is well-documented to lower the seizure threshold[7] and psychedelics may act to trigger seizures in susceptible individuals.[citation needed]

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Brazil: As of December 10, 2018, 25C-NBOH has been added to Portaria SVS/MS nº 344. Possession, distribution and use of this substance is now considered illegal.[8]
  • Germany: 25C-NBOH is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016.[9][10] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[11]
  • Sweden: The Riksdag added 25C-NBOH to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of August 18, 2015, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:12[12]
  • Switzerland: 25C-NBOH is a controlled substance specifically named under Verzeichnis E.[13]
  • United Kingdom: 25C-NBOH is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[14]

See also

References

  1. 1.0 1.1 1.2 Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths 
  2. Hansen, M. (2010). Design and synthesis of selective serotonin receptor agonists for positron emission tomography imaging of the brain: PhD thesis. Faculty of Pharmaceutical Sciences, University of Copenhagen. ISBN 9788792719003. 
  3. 3.0 3.1 Erowid 25I-NBOMe (2C-I-NBOMe) Vault : Fatalities / Deaths 
  4. 4.0 4.1 Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault : Fatalities / Deaths 
  5. Silva, M. E., Heim, R., Strasser, A., Elz, S., Dove, S. (January 2011). "Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor". Journal of Computer-Aided Molecular Design. 25 (1): 51–66. doi:10.1007/s10822-010-9400-2. ISSN 0920-654X. 
  6. Hansen, M., Phonekeo, K., Paine, J. S., Leth-Petersen, S., Begtrup, M., Bräuner-Osborne, H., Kristensen, J. L. (19 March 2014). "Synthesis and Structure–Activity Relationships of N -Benzyl Phenethylamines as 5-HT 2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. ISSN 1948-7193. 
  7. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  8. List of controlled substances: Portaria SVS/MS nº 344 (Portuguese) | http://portal.anvisa.gov.br/lista-de-substancias-sujeitas-a-controle-especial
  9. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in Deutsch). Bundesanzeiger Verlag. Retrieved December 11, 2019. 
  10. "Anlage NpSG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  11. "§ 4 NpSG" (in Deutsch). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  12. https://lakemedelsverket.se/upload/lvfs/HSLF_FS_2015_12.pdf
  13. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in Deutsch). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  14. Misuse of Drugs Act 1971 (S.I. 2014/1106), London: The Stationery Office Limited, 2014, retrieved 5 July 2017